A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. We have approved medicines for cystic fibrosis (“CF”), sickle cell disease (“SCD”), transfusion dependent beta thalassemia (“TDT”), and acute pain, and we continue to serially innovate and advance next-generation clinical and research programs in these areas. Our mid- and late-stage clinical pipeline includes programs across a range of modalities in additional serious diseases, including IgA nephropathy, APOL1-mediated kidney disease, neuropathic pain, type 1 diabetes, primary membranous nephropathy, autosomal dominant polycystic kidney disease, and myotonic dystrophy type 1. The following chart sets forth our approved products, clinical-stage programs, and select pre-clinical programs: We are advancing five pivotal programs across multiple disease areas: •IgA Nephropathy.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 12.0B | 12.0B | 11.0B | 9.9B | 8.9B | 7.6B |
| Net Income | 4.0B | 4.0B | -536M | 3.6B | 3.3B | 2.3B |
| EPS | $15.32 | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 |
| Free Cash Flow | 3.2B | 3.2B | -790M | 3.3B | 3.9B | 2.4B |
| ROIC | 22.9% | 29.1% | -3.2% | 44.4% | 84.8% | 68.0% |
| Gross Margin | 86.2% | 86.2% | 46.3% | 87.2% | 87.9% | 75.9% |
| Debt/Equity | 0.10 | 0.10 | 0.10 | 0.04 | 0.06 | 0.09 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 4.2B | 4.2B | -233M | 3.8B | 4.3B | 2.8B |
| Operating Margin | 34.8% | 34.8% | -2.1% | 38.8% | 48.2% | 36.7% |
| ROE | 21.2% | 22.5% | -3.3% | 20.6% | 23.9% | 23.2% |
| Shares Outstanding | 258M | 258M | 258M | 261M | 259M | 260M |
VERTEX PHARMACEUTICALS INC / MA passes 6 of 9 quality checks, suggesting mixed fundamentals.
VERTEX PHARMACEUTICALS INC / MA trades at 28.7x trailing earnings, compared to its 15-year median P/E of 24.6x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 35.0x vs a median of 33.8x. The company's 5-year average ROIC is 44.6% with a gross margin of 76.7%. Total shareholder yield (buybacks) is 1.8%. At current prices, the estimated annualized return to fair value is +13.8%.
VERTEX PHARMACEUTICALS INC / MA (VRTX) has a current P/E ratio of 28.7, compared to its historical median P/E of 24.6. The stock is currently considered Fair based on its historical valuation range.
VERTEX PHARMACEUTICALS INC / MA (VRTX) has a 5-year average return on invested capital (ROIC) of 44.6%. This indicates strong capital allocation and a potential competitive advantage.
VERTEX PHARMACEUTICALS INC / MA (VRTX) has a market capitalization of $113.6B. It is classified as a large-cap stock.
VERTEX PHARMACEUTICALS INC / MA (VRTX) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 1.78%.
Based on historical P/E analysis, VERTEX PHARMACEUTICALS INC / MA (VRTX) appears fair. The current P/E of 28.7 is 17% above its historical median of 24.6. The estimated fair value CAGR (P/E method) is 12.3%.
VERTEX PHARMACEUTICALS INC / MA (VRTX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported annual revenue of $12.0 billion in its most recent fiscal year, based on SEC EDGAR filings.
VERTEX PHARMACEUTICALS INC / MA (VRTX) has a net profit margin of 32.9%. This is a strong margin indicating high profitability.
VERTEX PHARMACEUTICALS INC / MA (VRTX) generated $3.2 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
VERTEX PHARMACEUTICALS INC / MA (VRTX) has a debt-to-equity ratio of 0.10. This indicates a conservatively financed balance sheet.
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported earnings per share (EPS) of $15.32 in its most recent fiscal year.
VERTEX PHARMACEUTICALS INC / MA (VRTX) has a return on equity (ROE) of 22.5%. This indicates the company generates strong returns for shareholders.
VERTEX PHARMACEUTICALS INC / MA (VRTX) has a 5-year average gross margin of 76.7%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 18 years of financial data for VERTEX PHARMACEUTICALS INC / MA (VRTX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
VERTEX PHARMACEUTICALS INC / MA (VRTX) has a book value per share of $72.34, based on its most recent annual SEC filing.
No recent press releases.